Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecular Psychiatry

• Publication date

  2017-02-28

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1038/mp.2017.6PMID 28242871
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exome Sequence Data From Multigenerational Families Implicate AMPA Receptor Trafficking in Neurocognitive Impairment and Schizophrenia Risk.

  2016cited by this paper
• Rhythmic Working Memory Activation in the Human Hippocampus.

  2015cited by this paper
• Cognitive impairment in schizophrenia: the great unmet need

  2015cited by this paper
• Brain rhythms connect impaired inhibition to altered cognition in schizophrenia.

  2015cited by this paper
• The discovery and characterization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242).

  2015cited by this paper
• Glutamate and dopamine in schizophrenia: An update for the 21st century

  2015cited by this paper
• Calibration and cross-validation of MCCB and CogState in schizophrenia

  2015cited by this paper
• Enhancing ketamine translational pharmacology via receptor occupancy normalization.

  2014cited by this paper
• α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazoleproprionic acid receptor activation protects against phencyclidine‐induced caspase‐3 activity by activating voltage‐gated calcium channels

  2014cited by this paper
• Reviewing the ketamine model for schizophrenia

  2014cited by this paper
• Loss of Phenotype of Parvalbumin Interneurons in Rat Prefrontal Cortex Is Involved in Antidepressant- and Propsychotic-Like Behaviors Following Acute and Repeated Ketamine Administration

  2014cited by this paper
• Positive Allosteric Modulation of AMPA Receptors from Efficacy to Toxicity: The Interspecies Exposure-Response Continuum of the Novel Potentiator PF-4778574

  2013cited by this paper
• Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiators.

  2013cited by this paper
• Ketamine alters oscillatory coupling in the hippocampus

  2013cited by this paper
• The NMDA receptor as a target for cognitive enhancement.

  2013cited by this paper
• Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

  2012cited by this paper
• CPP alters theta/gamma oscillations in rat hippocampus: simulation and experiment

  2012cited by this paper
• From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment

  2012cited by this paper
• Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

  2012cited by this paper
• Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence

  2012cited by this paper
• Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia.

  2012cited by this paper
• Ketamine Disrupts Theta Modulation of Gamma in a Computer Model of Hippocampus

  2011cited by this paper
• Delta oscillation and short-term plasticity in the rat medial prefrontal cortex: modelling NMDA hypofunction of schizophrenia.

  2011cited by this paper
• Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models.

  2010cited by this paper
• Working memory: the importance of theta and gamma oscillations.

  2010cited by this paper
• AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.

  2010cited by this paper
• Cross-frequency coupling supports multi-item working memory in the human hippocampus

  2010cited by this paper
• Positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor.

  2010cited by this paper
• Activity‐dependent synaptic plasticity of NMDA receptors

  2010cited by this paper
• Three Year Follow-Up Study of an Integrated Supported Employment for Individuals with Severe Mental Illness

  2010cited by this paper
• Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.

  2010cited by this paper
• Group 5 metabotropic glutamate receptors: role in modulating cortical activity and relevance to cognition.

  2010cited by this paper
• Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction.

  2010cited by this paper
• Review on Vocational Predictors: A Systematic Review of Predictors of Vocational Outcomes Among Individuals with Schizophrenia: An Update Since 1998

  2010cited by this paper
• Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex.

  2009cited by this paper
• A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia

  2008cited by this paper
• Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

  2007cited by this paper
• Psychiatric safety of ketamine in psychopharmacology research

  2007cited by this paper
• Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.

  2007cited by this paper
• Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior.

  2007cited by this paper
• Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.

  2007cited by this paper
• Greater vulnerability to the amnestic effects of ketamine in males

  2006cited by this paper
• Acute and chronic effects of ketamine upon human memory: a review

  2006cited by this paper
• Ampakines and the threefold path to cognitive enhancement.

  2006cited by this paper
• Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data

  2005cited by this paper
• Defining a cognitive function decrement in schizophrenia.

  2005cited by this paper
• Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.

  2005cited by this paper
• Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

  2005cited by this paper
• Expression profile of AMPA receptor subunit mRNA in single adult rat brain and spinal cord neurons in situ.

  2005cited by this paper
• The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

  2004cited by this paper
• Synaptic basis of persistent activity in prefrontal cortex in vivo and in organotypic cultures.

  2003cited by this paper
• NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

  2003cited by this paper
• Long-term potentiation and memory.

  2003cited by this paper
• Memory enhancement: the search for mechanism-based drugs

  2002cited by this paper
• AMPA receptor trafficking and synaptic plasticity.

  2002cited by this paper
• A Placebo-Controlled Pilot Study of the Ampakine CX516 Added to Clozapine in Schizophrenia

  2001cited by this paper
• Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

  2000cited by this paper
• Glutamate receptor expression in schizophrenic brain.

  2000cited by this paper
• Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

  2000cited by this paper
• Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Enhancement of Delayed-Nonmatch-to-Sample Performance

  1998cited by this paper
• Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS)

  1998cited by this paper
• Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Correlations with Hippocampal Neuronal Activity

  1998cited by this paper
• Neurocognitive Deficit in Schizophrenia: A Quantitative Review of the Evidence

  1998cited by this paper
• Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

  1998cited by this paper
• Psychological effects of a drug that facilitates brain AMPA receptors

  1996cited by this paper
• Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

  1994cited by this paper
• The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms.

  1991cited by this paper
• The Positive and Negative Syndrome Scale (PANSS): Rationale and Standardisation

  1989cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Opposing Modulation of EEG Aperiodic Component by Ketamine and Thiopental: Implications for the Noninvasive Assessment of Cortical E/I Balance in Humans

  2025cites this paper
• Positive AMPA and Kainate Receptor Modulators and Their Therapeutic Potential in CNS Diseases: A Comprehensive Review

  2025cites this paper
• Opposing Modulation of EEG Aperiodic Component by Ketamine and Thiopental: Implications for the Noninvasive Assessment of Cortical E/I Balance in Humans

  2025cites this paper
• IUPHAR Review - Novel therapeutic targets for schizophrenia treatment: a translational perspective.

  2025cites this paper
• Explainable Machine Learning Models for Malware Identification in Modern Computing Systems

  2025cites this paper
• Neuroimaging biomarkers for drug discovery and development in Schizophrenia.

  2024cites this paper
• AMPA receptor neurotransmission and therapeutic applications: A comprehensive review of their multifaceted modulation.

  2024cites this paper
• Synthesis of [11C]BIIB104, an α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic-Acid-Positive Allosteric Modulator, and Evaluation of the Bio-Distribution in Non-Human Primate Brains Using Positron Emission Tomography

  2024cites this paper
• Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities

  2024cites this paper
• The role of biomarkers in clinical development of drugs for neuropsychiatric disorders - A pragmatic guide.

  2024cites this paper
• Altered excitatory and inhibitory ionotropic receptor subunit expression in the cortical visuospatial working memory network in schizophrenia

  2024cites this paper
• Radiolabel Uncovers Nonintuitive Metabolites of BIIB104: Novel Release of [14C]Cyanide from 2-Cyanothiophene and Subsequent Formation of [14C]Thiocyanate

  2024cites this paper
• Targeting synapse function and loss for treatment of neurodegenerative diseases

  2023cites this paper
• Repeated dextromethorphan administration in adolescent rats produces long-lasting behavioral alterations

  2023cites this paper
• Cerebellar glutamatergic system impacts spontaneous motor recovery by regulating Gria1 expression

  2022cites this paper
• Mechanism of psychoactive substance-induced cognitive disorders: does tau protein play a role?

  2022cites this paper
• Distinct contributions of GluA1-containing AMPA receptors of different hippocampal subfields to salience processing, memory and impulse control

  2022cites this paper
• Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics

  2022cites this paper
• Advantages and Limitations of Animal Schizophrenia Models

  2022cites this paper
• Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia

  2022cites this paper
• Beyond NMDA Receptors: Homeostasis at the Glutamate Tripartite Synapse and Its Contributions to Cognitive Dysfunction in Schizophrenia

  2022cites this paper
• Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant.

  2022cites this paper
• Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: a long and winding road.

  2021cites this paper
• AMPA Receptor Potentiators as Potential Rapid-Acting Antidepressants

  2021cites this paper
• Progress in mechanistically novel treatments for schizophrenia.

  2021cites this paper
• Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels

  2021cites this paper
• Exploring the relation between BOLD fMRI and cognitive performance using a computer-based quantitative systems pharmacology model: Applications to the COMTVAL158MET genotype and ketamine.

  2021cites this paper
• Modulating inhibitory response control through potentiation of GluN2D subunit-containing NMDA receptors.

  2020cites this paper
• The Effects of General Anesthetics on Synaptic Transmission

  2020cites this paper
• Differential effects of glutamate N-methyl-d-aspartate receptor antagonists on risky choice as assessed in the risky decision task

  2020cites this paper
• Differential effects of glutamate N-methyl-d-aspartate receptor antagonists on risky choice as assessed in the risky decision task

  2020cites this paper
• Redistribution of Monocarboxylate 1 and 4 in Hippocampus and Spatial Memory Impairment Induced by Long-term Ketamine Administration

  2020cites this paper
• Auxiliary Proteins are the Predominant Determinants of Differential Efficacy of Clinical Candidates Acting as AMPA Receptor Positive Allosteric Modulators

  2020cites this paper
• TAK-137, an AMPA receptor potentiator with little agonistic effect, produces antidepressant-like effect without causing psychotomimetic effects in rats.

  2019cites this paper
• Long-lasting effects of repeated ketamine administration in adult and adolescent rats.

  2019cites this paper
• Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine.

  2019cites this paper
• Long-term potentiation prevents ketamine-induced aberrant neurophysiological dynamics in the hippocampus-prefrontal cortex pathway in vivo

  2019cites this paper
• Electrophysiological characterization of a novel AMPA receptor potentiator, TAK-137, in rat hippocampal neurons

  2019cites this paper
• Long-term ketamine administration causes Tau protein phosphorylation and Tau protein-dependent AMPA receptor reduction in the hippocampus of mice.

  2019cites this paper
• Preclinical characterization of AMPA receptor potentiator TAK‐137 as a therapeutic drug for schizophrenia

  2019cites this paper
• Reverse and Forward Translational Neuropharmacology in Psychiatric Drug Discovery

  2018cites this paper
• Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert.

  2018cites this paper
• Neurotoxic Agent-Induced Injury in Neurodegenerative Disease Model: Focus on Involvement of Glutamate Receptors

  2018cites this paper
• The profile of cognitive impairments in chronic ketamine users.

  2018cites this paper